Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.82 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.82 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.82 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.82 |
| ▸ | PFKP | Q01813 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.82 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.82 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.82 |
| ▸ | AKT1 | P31749 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528036 | 1.00 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30405708 | 1.00 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30324961 | 1.00 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL2903741 | 1.00 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL30353306 | 0.99 | MTOR (0.98) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL20552839 | 0.99 | MTOR (0.98) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL21528037 | 0.99 | MTOR (0.98) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL2905753 | 0.92 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL20734887 | 0.92 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30324973 | 0.92 | MTOR (1.00) | MTORPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | MTOR 53/4885PIK3CD 93/4885PIK3R1 189/4885 |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | MTOR 66/4885PIK3CD 80/4885PIK3R1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.